MedPage Today -- ROME -- Gout patients receiving treatment with standard allopurinol therapy appear to have a reduced risk of disease flares if they are treated with the investigative monoclonal antibody canakinumab, researchers said here.
MedPage Today -- ROME -- Gout patients receiving treatment with standard allopurinol therapy appear to have a reduced risk of disease flares if they are treated with the investigative monoclonal antibody canakinumab, researchers said here.
